Turing's former general counsel told Senate lawmakers that the fiftyfold price increase on Daraprim, a drug used to treat a life-threatening parasitic infection, "was certainly unjustified."
Howard Dorfman said that he and other staffers objected to the increase because it would have "a severely negative impact on Turing's business and reputation." But their concerns were overruled by Shkreli. Dorfman said he was fired from the company last August, shortly after raising his concerns.
Read Full Article »